Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may reveal who is at risk from severe abdominal infections

NCT ID NCT07689266

Knowledge-focused Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at whether certain immune checkpoint molecules found in the blood can help predict how serious an intra-abdominal infection is and the risk of death. Researchers will measure 10 different molecules in 75 patients with these infections. The goal is to better understand the body's immune response during severe infections, which could eventually lead to improved monitoring or treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain immune molecules are strongly linked to worse outcomes, this could point toward new ways to monitor or treat severe infections.
What could go wrong
This is a small observational study, not a treatment trial. It can only show associations, not cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

75 people

The number who actually took part.

Started

Dec 2023

Finished

Aug 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with intraabdominal infections due to gastrointestinal pathologies

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with intraabdominal infections due to gastrointestinal pathologies Exclusion Criteria: * Malignities * Pregnancy * Immune deficiency * Patients without intraabdominal infections

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intra abdominal infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intestinal perforation Intraabdominal Infections Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intra abdominal infections

Contacts and locations

Locations

  • Istanbul Training and Research Hospital

    Istanbul, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.